Plain-English translation of NCT02514239 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested a new medication called given through an IV (into the vein) for patients with multiple myeloma that had returned or stopped responding to at least two previous treatments. Researchers studied different doses of the medication to find the highest dose that patients could safely tolerate, while also measuring how the drug moved through the body and whether it helped shrink the cancer.
Multiple myeloma is a blood cancer that often comes back or becomes resistant to standard treatments, leaving patients with few options. This trial was designed to explore whether this new medication could offer hope to people whose disease no longer responds to existing therapies.
Participants received the medication as a continuous infusion through an IV line. The trial tested 13 different dose levels, starting very low and gradually increasing to find the safest dose; participants were assigned to one of these dose groups. Participants attended regular clinic visits where researchers monitored their health, drew blood samples to check how the drug worked in their body, and assessed whether their cancer was responding to treatment.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
France
Germany